Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong maintains an Equal-Weight rating on Nevro (NYSE:NVRO) and lowers the price target from $29 to $23.
August 04, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Nevro and lowered the price target from $29 to $23.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock price of Nevro in the short term. This is likely to negatively impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100